CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 12, 2015
Result type: Reports
Project Number: SE0446-000
Product Line: Reimbursement Review

Generic Name: Filgrastim

Brand Name: Grastofil

Manufacturer: Apotex Inc.

Therapeutic Area: Neutropenia

Indications: Prevention or treatment of neutropenia in various indications

Submission Type: Initial

Project Status: Complete

Biosimilar: Yes

Date Recommendation Issued: March 18, 2016

Recommendation Type: List with clinical criteria and/or conditions